SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike M who wrote (2605)9/14/2000 11:27:53 PM
From: DanZ  Read Replies (1) of 5582
 
I agree that it's completely different this year. Gum Tech should begin producing nicotine gum for the Swedish Match joint venture in the first quarter of 2001 and they are closer to signing a supply contract for dental gum with the yet to be named large consumer products company. Add in Zicam Allergy Relief and I don't see a seasonal company any more. One of these days, GUMM is going to break out of its trading range and forge new ground. My bet is that we are in the early stages of that move now. The size of the cold remedy market is about $3 billion. The size of the allergy market is about $2.5 billion. The size of the nicotine cessation market is about $700 million and is projected to grow to $1.5 billion by 2007. With only about 10 million shares outstanding and excellent products targeted at each market, this company has plenty of earnings leverage.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News